Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR

Vir Biotechnology

Vir Biotechnology clinical programs — 34 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1800 Owens St, Suite 900, San Francisco, California 94158, US HQ
2016 Founded
479 Employees
Public company Type
VIR · NYSE Ticker
Company details
Status
Public
HQ
1800 Owens St, Suite 900, San Francisco, California 94158, US
Founded
2016
Employees
479
Programs
34
Drugs
17
Patents
6
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vir Biotechnology projects

34 ClinicalTrials.gov programs sponsored by Vir Biotechnology.

Vir Biotechnology has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

34 programs

Clinical programs

  1. LY3819253

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  2. Tobevibart

    Vir Biotechnology

    Viral Hepatitis

    phase 3 small molecule active

    3 trials

  3. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  4. VIR-7831

    Vir Biotechnology

    COVID-19

    phase 3 mab completed

    1 trial

  5. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  6. VIR-CHDV-V205

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  7. sotrovimab

    Vir Biotechnology

    Covid19

    phase 3 mab terminated

    3 trials

  8. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  9. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  10. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  11. PEG-IFNα

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  12. Sotrovimab

    Vir Biotechnology

    COVID-19

    phase 2 mab terminated

    1 trial

  13. Sotrovimab (Gen1)

    Vir Biotechnology

    Covid19

    phase 2 mab completed

    1 trial

  14. Tenofovir Alafenamide

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  15. VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  16. VIR-2218

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  17. VIR-2218

    Vir Biotechnology

    Hepatitis D, Chronic

    phase 2 small molecule active

    1 trial

  18. VIR-2218-1006

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  19. VIR-2482 (450 mg)

    Vir Biotechnology

    Influenza A

    phase 2 mab terminated

    1 trial

  20. VIR-3434

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  21. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  22. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  23. VIR-CHDV-V206

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  24. VIR-MHB1-V200

    Vir Biotechnology

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

  25. Sotrovimab

    Vir Biotechnology

    COVID-19 Infection

    phase 1 mab terminated

    1 trial

  26. VIR-1111

    Vir Biotechnology

    HIV I Infection

    phase 1 mab completed

    1 trial

  27. VIR-2218

    Vir Biotechnology

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  28. VIR-2218

    Vir Biotechnology

    Hepatic Impairment

    phase 1 small molecule active

    1 trial

  29. VIR-2482

    Vir Biotechnology

    Influenza A

    phase 1 small molecule completed

    1 trial

  30. VIR-3434

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab completed

    1 trial

  31. VIR-5500

    Vir Biotechnology

    Hormone-refractory Prostate Cancer

    phase 1 small molecule active

    1 trial

  32. VIR-5525

    Vir Biotechnology

    Solid Tumor Malignancies

    phase 1 small molecule active

    1 trial

  33. VIR-5818-V101

    Vir Biotechnology

    Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 1 other active

    1 trial

  34. VRON-0200-AdC6

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Vir Biotechnology have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.